Lieza Danan

Prior to her position as co-founder and CEO of LiVeritas Biosciences, Lieza, a serial biotech entrepreneur in the San Francisco Bay Area, held scientific operations and strategic advisory leadership roles in the biopharma industry for over 10 years and honed her expertise in mass spectrometry analytics for two decades. As Co-Founder & CEO/COO/CSO at InterVenn, Dr. Danan spring-boarded the AI-driven glycoproteomic platform company from Seed to Series A, raising $9.4 million. Serving as a mass spec function lead and key contributor to biotech startups Stemcentrx (acquired by AbbVie) and Sutro Biopharma (IPO), she made a name for herself as a leading authority on phase-appropriate implementation of mass spec in drug development. While the Genentech Pilot Site Lead and Principal Scientist at Eurofins Lancaster Laboratories, Lieza developed a strong interest in all phases of drug development.

She holds a Ph.D. in Biological Chemistry from the University of California at Davis and a B.S. in Chemistry (Honors Program) from the Ateneo De Manila University. Lieza’s other passions include empowering Asian-American leaders in the sciences toward entrepreneurship using holistic approaches, including positive psychology and spirituality. To reset, she plays with her orange tabby, KB, named in honor of Prof. Klaus Biemann, one of the Founding Fathers of Mass Spectrometry.